Page 83 - 2018_09-Mondo

Inhibition of DHODH induces differentiation in AML
ture predicts survival in cytogenetically nor- mal acute myeloid leukemia. Blood. 2008;112(10):4193-4201.
21. Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sen- sitivity. Nature. 2012;483(7391):603-607.
22. Wu S, Cetinkaya C, Munozalonso MJ, et al. Myc represses differentiation-induced p21 CIP1 expression via Miz-1-dependent inter- action with the p21 core promoter. Oncogene. 2003;22(3):351-360.
23. Cancer Genome Atlas Research N, Ley TJ, Miller C, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059- 2074.
24. Seoane J, Le HV, Massagué J. Myc suppres- sion of the p21 (Cip1) Cdk inhibitor influ- ences the outcome of the p53 response to DNA damage. Nature. 2002;419(6908):729- 734.
25. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, ran- domised, multicentre trial. Lancet. 1999;353 (9149):259-266.
26. Grøftehauge MK, Hajizadeh NR, Swann MJ, Pohl E. Protein–ligand interactions investi- gated by thermal shift assays (TSA) and dual polarization interferometry (DPI). Acta Crystallogr D Biol Crystallogr. 2015;71 (1):36-44.
27. Guo Z-Q, Zheng T, Chen B, et al. Small- molecule targeting of E3 ligase adaptor SPOP in kidney cancer. Cancer Cell. 2016;30(3):474-484.
28. K Vyas V, Ghate M. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors. Mini Rev Med Chem. 2011;11(12):1039-1055.
29. Sun Y, Hess JL. Targeting the pyrimidine synthesis pathway for differentiation thera- py of acute myelogenous leukemia. Transl Cancer Res. 2017;6(1):S109-S111.
30. Dang CV. MYC on the path to cancer. Cell. 2012;149(1):22-35.
31. Itkonen H M, Minner S, Guldvik I J, et al. O- GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells. Cancer Res. 2013;73(16):5277-5287.
32. Józ´wiak P, Forma E, Bry M, et al. O- GlcNAcylation and metabolic reprograming in cancer. Front Endocrinol. 2014;5(5):145.
33. Chou T-C. Drug combination studies and their synergy quantification using the Chou- Talalay method. Cancer Res. 2010;70(2): 440-446.
34. de Thé H. Differentiation therapy revisited. Nat Rev Cancer. 2018;18(2):117-127.
35. Vita M, Henriksson M. The Myc oncopro- tein as a therapeutic target for human can- cer. Semin Cancer Biol. 2006;16(4):318-330.
36. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic dis-
ease. Oncogene. 1999;18(19):3004-3016.
37. Yu Z-Y, Xiao H, Wang L-M, et al. Natural product vibsanine A induces differentiation of myeloid leukemia cells through PKC acti-
vation. Cancer Res. 2016;76(9):2698-2709. 38. White RM, Cech J, Ratanasirintrawoot S, et al. DHODH modulates transcriptional elon- gation in the neural crest and melanoma.
Nature. 2011;471(7339):518-522.
39. Akihisa T, Tokuda H, Hasegawa D, et al. Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects. J Nat Prod. 2006;
69(1):38-42.
40. Jing H, Zhou X, Dong X, et al. Abrogation of
Akt signaling by isobavachalcone con- tributes to its anti-proliferative effects towards human cancer cells. Cancer Lett. 2010;294(2):167-177.
41. Brown KK, Spinelli JB, Asara J, Toker A. Adaptive reprogramming of de novo pyrim- idine synthesis is a metabolic vulnerability in triple-negative breast cancer. Cancer Discov. 2017;7(4):391-399.
42. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 2006;6(3): 184-192.
43. Mathur D, Stratikopoulos E, Ozturk S, et al. PTEN regulates glutamine flux to pyrimi- dine synthesis and sensitivity to dihydrooro- tate dehydrogenase inhibition. Cancer Discov. 2017;7(4):380-390.
haematologica | 2018; 103(9)
1483